170 related articles for article (PubMed ID: 37223641)
1. A Platinum Resistance-Related lncRNA Signature for Risk Classification and Prognosis Prediction in Patients with Serous Ovarian Cancer.
Zhu Y; Chen J; Zhou L; Zhang L; Liu Y; Zhuang Y; Peng L; Huang YT
J Oncol; 2022; 2022():7625138. PubMed ID: 37223641
[TBL] [Abstract][Full Text] [Related]
2. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
3. A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer.
Du X; Pu X; Wang X; Zhang Y; Jiang T; Ge Y; Zhu H
Front Genet; 2022; 13():938250. PubMed ID: 36561319
[No Abstract] [Full Text] [Related]
4. An autophagy-related four-lncRNA signature helps to predict progression-free survival of neuroblastoma patients.
Wang J; Meng X; Chen K; Feng J
Front Oncol; 2022; 12():1014845. PubMed ID: 36530992
[TBL] [Abstract][Full Text] [Related]
5. A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer.
Luo J; Peng J; Xiao W; Huang S; Cao Y; Wang T; Wang X
Front Genet; 2022; 13():984696. PubMed ID: 36092933
[No Abstract] [Full Text] [Related]
6. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
7. A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer.
Zeng J; Li M; Dai K; Zuo B; Guo J; Zang L
Pathol Oncol Res; 2022; 28():1610643. PubMed ID: 36419649
[No Abstract] [Full Text] [Related]
8. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
Front Oncol; 2022; 12():966920. PubMed ID: 36276132
[TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of a Prognostic lncRNA Signature for Hepatocellular Carcinoma.
Li W; Chen QF; Huang T; Wu P; Shen L; Huang ZL
Front Oncol; 2020; 10():780. PubMed ID: 32587825
[No Abstract] [Full Text] [Related]
10. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
11. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
[TBL] [Abstract][Full Text] [Related]
12. Construction of prognostic signature of breast cancer based on N7-Methylguanosine-Related LncRNAs and prediction of immune response.
Cao J; Liang Y; Gu JJ; Huang Y; Wang B
Front Genet; 2022; 13():991162. PubMed ID: 36353118
[No Abstract] [Full Text] [Related]
13. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma.
Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y
Front Surg; 2022; 9():860806. PubMed ID: 35937602
[TBL] [Abstract][Full Text] [Related]
14. Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma.
Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
Front Oncol; 2021; 11():663263. PubMed ID: 34123820
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Novel Glycolysis-Related LncRNA Signature for Predicting Overall Survival in Patients With Bladder Cancer.
Zheng Z; Lai C; Li W; Zhang C; Ma K; Yao Y
Front Genet; 2021; 12():720421. PubMed ID: 34490046
[TBL] [Abstract][Full Text] [Related]
16. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
17. Construction and validation of a glycolysis-related lncRNA signature for prognosis prediction in Stomach Adenocarcinoma.
Liao T; Lu Y; Li W; Wang K; Zhang Y; Luo Z; Ju Y; Ouyang M
Front Genet; 2022; 13():794621. PubMed ID: 36313430
[No Abstract] [Full Text] [Related]
18. Development of a novel five-lncRNA prognostic signature for predicting overall survival in elderly patients with breast cancer.
Luo Y; Zhang Y; Wu YX; Li HB; Shen D; Che YQ
J Clin Lab Anal; 2022 Jan; 36(1):e24172. PubMed ID: 34894405
[TBL] [Abstract][Full Text] [Related]
19. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
Yan J; Zhou C; Guo K; Li Q; Wang Z
J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
